 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2019, vol. 25, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2019252.2537
Published online: 07 May 2019
Case report
J of IMAB. 2019 Apr-Jun;25(2):2537-2543
IMPACT OF CARRIAGE OF 4G/5G PAI-1 AND GLYCOPROTEIN IIB/IIIA POLYMORPHISM ON DEVELOPMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PATIENT WITH PSORIASIS VULGARIS. Clinical Case.
Borislav Dimitrov1
, Kalina Ilieva2, Dimitar Gospodinov3, Regina Komsa-Penkova1,
1) Department of Chemistry/Biochemistry University of Medicine, Pleven, Bulgaria.
2) Department of Аnatomy, Histology, Cytology and Biology University of Medicine, Pleven, Bulgaria.
3 Department of Dermatology, Venerology and Allergology University of Medicine, Pleven, Bulgaria.
ABSTRACT:
Psoriasis vulgaris represents a chronic immune-inflammatory condition that besides skin and joints, also affects many other tissues and organs. Recent advances in psoriatic research highlighted that psoriatic patients are at higher risk to develop the chronic obstructive pulmonary disease (COPD). We report a case of a Caucasian man of 62 years’ age with plaque psoriasis diagnosed more than 20 years who developed psoriasis specific comorbidities: COPD in 2005 and later in 2006 arterial hypertension and ischemic cardiomyopathy disease.
The patient’s blood parameters were specific for psoriasis and metabolic syndrome with high total cholesterol 6.13 mmol/L, high triglycerides 2.37 mmol/L, high LDL 4.7 mmol/L, low HDL-cholesterol 0.79 mmol/L. Enzyme-linked immunosorbent assay (ELISA) analysis demonstrated elevated serum plasminogen activator inhibitor 1 (PAI-1) levels – 63.21 ng/ml (ref.5-40 ng/mL). The DNA analysis revealed a carriage of heterozygous polymorphism in PAI-1 4G/5G and a carriage of heterozygous polymorphism PlA1/PlA2 in the gene for glycoprotein IIb/IIIa.
This case on psoriasis and comorbidity is an example concerning the possible connection of impact of inherited factors with an increased risk of COPD.
Keywords: psoriasis, COPD, ischaemic heart disease, 4G/5G PAI-1, PlA1/PlA2,
- Download FULL TEXT /PDF 1354 KB/
Please cite this article as: Dimitrov B, Ilieva K, Gospodinov D, Komsa-Penkova R. Impact of carriage of 4G/5G PAI-1 and Glycoprotein IIb/IIIa polymorphism on development of Chronic Obstructive Pulmonary Disease in a patient with psoriasis vulgaris. J of IMAB. 2019 Apr-Jun;25(2):2537-2543. DOI: 10.5272/jimab.2019252.2537
Correspondence to: Borislav Tsvetanov Dimitrov, Assistant Professor at Department of Chemistry & Biochemistry, Medical University – Pleven; 1, St. Kliment Ohridski, Str. 5800 Pleven, Bulgaria; E-mail: bobi.tsvetanov@gmail.com
REFERENCES:
1. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014 Apr;7:119-32. [PubMed] [Crossref]
2. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol. 2009 Jul;129(7):1601-3. [PubMed]
3. Garima P. Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol. 2013 Jul;58(4):299-305. [PubMed] [Crossref]
4. Santus P, Rizzi M, Radovanovic D, Airoldi A, Cristiano A, Conic R, et al. Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy. Biomed Res Int. 2018 Sep 23;2018:3140682. [PubMed] [Crossref]
5. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, et al. (2012) Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS One. 7(5): e37483. [PubMed] [Crossref]
6. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-55. [PubMed] [Crossref]
7. Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:271918. [PubMed]
8. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008 Sep;159(4):956-60. [PubMed] [Crossref]
9. Komsa-Penkova R, Kovacheva К, Kotseva K, Angelova S, Savov A, Semionova M. [Selected methods of DNA analysis and clinical applications.] [in Bulgarian] 1st ed. MU Pleven. 2004.
10. Vaughan DE. PAI-1 and atherotrombosis. J Tromb Haemost. 2005 Aug;3(8):1879-83. [PubMed] [Crossref]
11. Nielsen H, Christensen I, Svendsen M, Hansen U, Werther K, Brünner N. et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 2002; 51(11):563-7. [PubMed]
12. Nielsen H, Christensen I, Svendsen M, Hansen U, Werther K, Brünner N. et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 2002 Nov;51(11):563-7. [PubMed]
13. Huotari A, Lehto S, Niskanen L, Herzig K, Hintikka J, Koivumaa-Honkanen H. Et all. Increased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based Study. Cardiovasc Psychiatry Neurol. 2010;2010:501349. [PubMed]
14. Waschki B, Watz H, Holz O, Magnussen H, Olejnicka B, Welte T, et al. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:981-987. [PubMed] [Crossref]
15. Xu X, Wang H, Wang Z, Xiao W. Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipoplysaccharides in alveolar epithelial cells. Exp Lung Res. 2009 Nov; 35(9):795-805. [PubMed] [Crossref]
16. Tsantes A, Nikolopoulos G, Bagos P, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008; 122(6):736-42.
17. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T and Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 2004 Jun;150(6):793-8. [PubMed]
18. Goldschmidt-Clermont J, Coleman D, Pham M, Cooke E, Shear S, Weiss J. et al. Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Arch Pathol Lab Med. 1999 Dec;123(12):1223-9. [PubMed] [Crossref]
19. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):152-6. [PubMed]
20. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpainter K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997; 349: 385–88.
21. Hu Y, Yin L, Xu J, Yin Z. Renal function of psoriatic patients: erythrodermic psoriasis has more significant hyperuricemia. Biomedical Research. 2017; 28 (6): 2515-2518.
22. Shrestha S, Gyawali P, Shrestha R, Poudel B, Sigdel M, Regmi P. et al. Serum Urea and Creatinine in Diabetic and non-diabetic Subjects. JNAMLS. 2008;9(11):11–12.
23. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992 Oct;90(4):1323-7. [PubMed] [Crossref]
24. Piskin S, Gurkok F, Ekuklu G, and Senol M. Serum Lipid Levels in Psoriasis. Yonsei Medical Journal . 2003; 44: 24-26.
25. Prevalence of the Metabolic Syndrome in PsoriasisResults From the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147(4):419-24.
26. Chiang Y, Lin W. Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2012;26:59–65.
27. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373–377.
28. Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol. 2011;30:877–885.
29. Li X, Kong L, Li F, Chen C, Xu R, Wang H, et al. Association between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. PLoS One. 2015 Dec 23;10(12):e0145221. [PubMed] [Crossref]
30. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37:146–155.
31. Machado-Pinto J, Diniz Mdos S, Bavoso NC. Psoriasis: new comorbidities. An Bras Dermatol. 2016 Jan-Feb;91(1):8-14. [PubMed] [Crossref]
32. Li X, Fan X, Zhang K, Yin G, Liu Y. Influence of psoriatic peripheral blood CD4+ T and CD8+ T lymphocytes on C-myc, Bcl-xL and Ki67 gene expression in keratinocytes. Eur J Dermatol. 2007;17:392-6.
33. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007 Dec;204(13):3183-94. [PubMed]
34. Fabbri L, Luppi F, Beghe B, Rabe K. Complex chronic comorbidities of COPD. Eur Respir J. 2008 Jan;31(1):204-12. [PubMed]
35. Mukhopadhyay S, Hoidal J, Mukherjee T. Role of TNFα in pulmonary pathophysiology. Respir Res. 2006 Oct;7:125. [PubMed]
36. Ha H, Neamati N. Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. Mol Pharm. 2014 Jul;11(7):2431-41. [PubMed] [Crossref]
37. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction.Eur Respir J. 2008; 31(6):1334–56. [PubMed]
38. Neimann A, Shin D, Wang X, Margolis D, Troxel A, Gelfand J. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-3. [PubMed] [Crossref]
39. Sin D, Man F,Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Circulation. 2003;107(11):1514-9. [PubMed]
40. Basili S, Ferroni P, Vieri M, Cardelli P, Ceci F, Paradiso M. et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999 Dec;147(2):249-52. [PubMed]
41. Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, Olesen JB, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011 Mar 25;6(3):e18125. [PubMed] [Crossref]
42. Zafirova-Ivanovska B, Stojkovikj J, Dokikj D, Anastasova S, Debresliovska A, Zejnel S, et al. The Level of Cholesterol in COPD Patients with Severe and Very Severe Stage of the Disease. Open Access Maced J Med Sci. 2016 Jun 15;4(2):277-82. [PubMed] [Crossref]
43. Mirrakhimov E. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol. 2012; 11:132
44. Akhyani M, Ehsani A, Robati M, Robati M. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;10:1330-1332.
45. Calles-Escandon J, Mirza S, Sobel B, Schneider D. Induction of Hyperinsulinemia Combined With Hyperglycemia and Hypertriglyceridemia Increases Plasminogen Activator Inhibitor 1 in Blood in Normal Human Subjects. Diabetes. 1998;47(2):290-3. [Crossref]
46. Kudo T, Nakayama E, Suzuki S, Akiyama, Shibata S. Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver. Am j Physiol Endocrinol Metab. 2004 287(4): 644-51.
47. Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008; 2:10-7.
48. Oh C, Das K, Gottlieb A. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000; 42(5):829-30.
49. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012; 147:179-87.
Received: 26 November 2018
Published online: 07 May 2019